

Global Tumor Biomarker Testing Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G395A9EEA87DEN.html>

Date: May 2026

Pages: 205

Price: US\$ 4,480.00 (Single User License)

ID: G395A9EEA87DEN

Abstracts

The global Tumor Biomarker Testing market size is expected to reach \$ 24843 million by 2032, rising at a market growth of 10.4% CAGR during the forecast period (2026-2032).

Tumor Biomarker Testing refers to the broad category of diagnostic products and testing services used to analyze measurable features associated with malignant tumors for diagnosis, classification, therapy selection, treatment monitoring, recurrence surveillance, and prognosis assessment. The analytes covered by Tumor Biomarker Testing may include protein markers, DNA mutations, RNA fusions, copy number variations, methylation signatures, microsatellite instability, tumor mutational burden, PD-L1 expression, circulating tumor DNA, and circulating tumor cells in tissue, blood, bone marrow, cells, or other body fluid samples. In commercial form, Tumor Biomarker Testing may appear as central-laboratory testing services, PCR kits, NGS panels, IHC/ISH reagents, cartridge-based automated systems, quality controls, and integrated software-reporting solutions. Its structure usually includes sample collection and preservation media, pre-analytical reagents, amplification or hybridization chemistry, signal detection instruments, bioinformatics interpretation modules, and clinical reporting. The core principle is to convert reproducible molecular or cellular abnormalities of cancer into clinically actionable information.

The growth of Tumor Biomarker Testing is fundamentally supported by the rising global cancer burden and the deeper penetration of precision oncology. With around 20 million new cancer cases worldwide in 2022 and a continued shift toward targeted therapy, immunotherapy, and biomarker-guided treatment, clinical practice is moving from single-gene testing toward comprehensive biomarker testing and comprehensive genomic profiling. Guideline adoption and expanding drug-label linkage are driving demand for

tissue testing, liquid biopsy, companion diagnostics, and MRD monitoring.

The major restraints remain access, reimbursement, standardization, and real-world implementation efficiency. Many patients still do not receive complete biomarker testing early enough in the treatment pathway, while tissue inadequacy, workflow fragmentation, inter-laboratory variability, low-shedding ctDNA, result interpretation complexity, and uneven payment coverage continue to limit adoption. For suppliers, regulatory compliance, evidence generation, quality systems, and secure data handling raise barriers to scale.

Downstream demand is shifting from one-time testing toward longitudinal, multi-sample, and multi-technology testing. Hospitals increasingly prefer integrated solutions that cover DNA, RNA, protein, and immune-related markers with faster turnaround and less tissue consumption. Advanced solid tumor care is moving toward broader pan-cancer panels and liquid biopsy, while post-surgical and treatment-monitoring settings are accelerating demand for ctDNA-MRD and recurrence surveillance. As a result, decentralized cartridge systems and centralized high-complexity genomic labs will continue to coexist, serving different clinical needs.

This report studies the global Tumor Biomarker Testing demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Tumor Biomarker Testing, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumor Biomarker Testing that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Tumor Biomarker Testing total market, 2021-2032, (USD Million)

Global Tumor Biomarker Testing total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Tumor Biomarker Testing total market, key domestic companies, and share, (USD Million)

Global Tumor Biomarker Testing revenue by player, revenue and market share 2021-2026, (USD Million)

Global Tumor Biomarker Testing total market by Type, CAGR, 2021-2032, (USD Million)

Global Tumor Biomarker Testing total market by Application, CAGR, 2021-2032, (USD

Million)

This report profiles major players in the global Tumor Biomarker Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Agilent Technologies, Roche, Thermo Fisher Scientific, QIAGEN, Illumina, DiaSorin, Fujirebio, Siemens Healthineers, Quest Diagnostics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Tumor Biomarker Testing market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Tumor Biomarker Testing Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Tumor Biomarker Testing Market, Segmentation by Type:

DNA Biomarker Testing

RNA Biomarker Testing

Protein Biomarker Testing

Cell-based Biomarker Testing

Multi-analyte Biomarker Testing

Global Tumor Biomarker Testing Market, Segmentation by Sample Source:

Tissue-based Testing

Blood-based Testing

Bone Marrow-based Testing

Other Body Fluid-based Testing

Global Tumor Biomarker Testing Market, Segmentation by Delivery Model:

Central Laboratory Testing

Hospital In-house Testing

Global Tumor Biomarker Testing Market, Segmentation by Detection Technology:

Sequencing-based Testing

PCR-based Testing

Immunoassay-based Testing

Hybridization-based Testing

Cell Analysis-based Testing

Global Tumor Biomarker Testing Market, Segmentation by Application:

Lung Cancer

Breast Cancer

Colorectal

Prostate Cancer

Blood Cancer

Companies Profiled:

Abbott Laboratories

Agilent Technologies

Roche

Thermo Fisher Scientific

QIAGEN

Illumina

DiaSorin

Fujirebio

Siemens Healthineers

Quest Diagnostics

Labcorp

NeoGenomics

Exact Sciences

Myriad Genetics

Guardant Health

Caris Life Sciences

Tempus AI

Natera

Personalis

Invivoscribe

Biocartis

Sysmex

Leica Biosystems

Cepheid

Menarini Silicon Biosystems

Veracyte

Castle Biosciences

OncoDNA

ACT Genomics

GC Genome

Burning Rock

Amoy Diagnostics

Genetron Health

3DMed Diagnostics

Singlera Genomics

BGI Genomics

Geneseeq

Genecast

Key Questions Answered

1. How big is the global Tumor Biomarker Testing market?
2. What is the demand of the global Tumor Biomarker Testing market?
3. What is the year over year growth of the global Tumor Biomarker Testing market?
4. What is the total value of the global Tumor Biomarker Testing market?
5. Who are the Major Players in the global Tumor Biomarker Testing market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Tumor Biomarker Testing Introduction
- 1.2 World Tumor Biomarker Testing Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Tumor Biomarker Testing Total Market by Region (by Headquarter Location)
 - 1.3.1 World Tumor Biomarker Testing Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company Tumor Biomarker Testing Revenue (2021-2032)
 - 1.3.3 China Based Company Tumor Biomarker Testing Revenue (2021-2032)
 - 1.3.4 Europe Based Company Tumor Biomarker Testing Revenue (2021-2032)
 - 1.3.5 Japan Based Company Tumor Biomarker Testing Revenue (2021-2032)
 - 1.3.6 South Korea Based Company Tumor Biomarker Testing Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company Tumor Biomarker Testing Revenue (2021-2032)
 - 1.3.8 India Based Company Tumor Biomarker Testing Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Tumor Biomarker Testing Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Tumor Biomarker Testing Consumption Value (2021-2032)
- 2.2 World Tumor Biomarker Testing Consumption Value by Region
 - 2.2.1 World Tumor Biomarker Testing Consumption Value by Region (2021-2026)
 - 2.2.2 World Tumor Biomarker Testing Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Tumor Biomarker Testing Consumption Value (2021-2032)
- 2.4 China Tumor Biomarker Testing Consumption Value (2021-2032)
- 2.5 Europe Tumor Biomarker Testing Consumption Value (2021-2032)
- 2.6 Japan Tumor Biomarker Testing Consumption Value (2021-2032)
- 2.7 South Korea Tumor Biomarker Testing Consumption Value (2021-2032)
- 2.8 ASEAN Tumor Biomarker Testing Consumption Value (2021-2032)
- 2.9 India Tumor Biomarker Testing Consumption Value (2021-2032)

3 WORLD TUMOR BIOMARKER TESTING COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Tumor Biomarker Testing Revenue by Player (2021-2026)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Tumor Biomarker Testing Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Tumor Biomarker Testing in 2025

3.2.3 Global Concentration Ratios (CR8) for Tumor Biomarker Testing in 2025

3.3 Tumor Biomarker Testing Company Evaluation Quadrant

3.4 Tumor Biomarker Testing Market: Overall Company Footprint Analysis

3.4.1 Tumor Biomarker Testing Market: Region Footprint

3.4.2 Tumor Biomarker Testing Market: Company Product Type Footprint

3.4.3 Tumor Biomarker Testing Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Tumor Biomarker Testing Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Tumor Biomarker Testing Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)

4.1.2 United States VS China: Tumor Biomarker Testing Revenue Market Share Comparison (2021 & 2025 & 2032)

4.2 United States Based Companies VS China Based Companies: Tumor Biomarker Testing Consumption Value Comparison

4.2.1 United States VS China: Tumor Biomarker Testing Consumption Value Comparison (2021 & 2025 & 2032)

4.2.2 United States VS China: Tumor Biomarker Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)

4.3 United States Based Tumor Biomarker Testing Companies and Market Share, 2021-2026

4.3.1 United States Based Tumor Biomarker Testing Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Tumor Biomarker Testing Revenue, (2021-2026)

4.4 China Based Companies Tumor Biomarker Testing Revenue and Market Share, 2021-2026

4.4.1 China Based Tumor Biomarker Testing Companies, Company Headquarters

(Province, Country)

4.4.2 China Based Companies Tumor Biomarker Testing Revenue, (2021-2026)

4.5 Rest of World Based Tumor Biomarker Testing Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Tumor Biomarker Testing Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Tumor Biomarker Testing Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 DNA Biomarker Testing

5.2.2 RNA Biomarker Testing

5.2.3 Protein Biomarker Testing

5.2.4 Cell-based Biomarker Testing

5.2.5 Multi-analyte Biomarker Testing

5.3 Market Segment by Type

5.3.1 World Tumor Biomarker Testing Market Size by Type (2021-2026)

5.3.2 World Tumor Biomarker Testing Market Size by Type (2027-2032)

5.3.3 World Tumor Biomarker Testing Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY SAMPLE SOURCE

6.1 World Tumor Biomarker Testing Market Size Overview by Sample Source: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Sample Source

6.2.1 Tissue-based Testing

6.2.2 Blood-based Testing

6.2.3 Bone Marrow-based Testing

6.2.4 Other Body Fluid-based Testing

6.3 Market Segment by Sample Source

6.3.1 World Tumor Biomarker Testing Market Size by Sample Source (2021-2026)

6.3.2 World Tumor Biomarker Testing Market Size by Sample Source (2027-2032)

6.3.3 World Tumor Biomarker Testing Market Size Market Share by Sample Source (2027-2032)

7 MARKET ANALYSIS BY DELIVERY MODEL

7.1 World Tumor Biomarker Testing Market Size Overview by Delivery Model: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Delivery Model

7.2.1 Central Laboratory Testing

7.2.2 Hospital In-house Testing

7.3 Market Segment by Delivery Model

7.3.1 World Tumor Biomarker Testing Market Size by Delivery Model (2021-2026)

7.3.2 World Tumor Biomarker Testing Market Size by Delivery Model (2027-2032)

7.3.3 World Tumor Biomarker Testing Market Size Market Share by Delivery Model (2027-2032)

8 MARKET ANALYSIS BY DETECTION TECHNOLOGY

8.1 World Tumor Biomarker Testing Market Size Overview by Detection Technology: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Detection Technology

8.2.1 Sequencing-based Testing

8.2.2 PCR-based Testing

8.2.3 Immunoassay-based Testing

8.2.4 Hybridization-based Testing

8.2.5 Cell Analysis-based Testing

8.3 Market Segment by Detection Technology

8.3.1 World Tumor Biomarker Testing Market Size by Detection Technology (2021-2026)

8.3.2 World Tumor Biomarker Testing Market Size by Detection Technology (2027-2032)

8.3.3 World Tumor Biomarker Testing Market Size Market Share by Detection Technology (2027-2032)

9 MARKET ANALYSIS BY APPLICATION

9.1 World Tumor Biomarker Testing Market Size Overview by Application: 2021 VS 2025 VS 2032

9.2 Segment Introduction by Application

9.2.1 Lung Cancer

9.2.2 Breast Cancer

9.2.3 Colorectal

9.2.4 Prostate Cancer

9.2.5 Blood Cancer

9.3 Market Segment by Application

9.3.1 World Tumor Biomarker Testing Market Size by Application (2021-2026)

9.3.2 World Tumor Biomarker Testing Market Size by Application (2027-2032)

9.3.3 World Tumor Biomarker Testing Market Size Market Share by Application (2021-2032)

10 COMPANY PROFILES

10.1 Abbott Laboratories

10.1.1 Abbott Laboratories Details

10.1.2 Abbott Laboratories Major Business

10.1.3 Abbott Laboratories Tumor Biomarker Testing Product and Services

10.1.4 Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.1.5 Abbott Laboratories Recent Developments/Updates

10.1.6 Abbott Laboratories Competitive Strengths & Weaknesses

10.2 Agilent Technologies

10.2.1 Agilent Technologies Details

10.2.2 Agilent Technologies Major Business

10.2.3 Agilent Technologies Tumor Biomarker Testing Product and Services

10.2.4 Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.2.5 Agilent Technologies Recent Developments/Updates

10.2.6 Agilent Technologies Competitive Strengths & Weaknesses

10.3 Roche

10.3.1 Roche Details

10.3.2 Roche Major Business

10.3.3 Roche Tumor Biomarker Testing Product and Services

10.3.4 Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.3.5 Roche Recent Developments/Updates

10.3.6 Roche Competitive Strengths & Weaknesses

10.4 Thermo Fisher Scientific

10.4.1 Thermo Fisher Scientific Details

10.4.2 Thermo Fisher Scientific Major Business

10.4.3 Thermo Fisher Scientific Tumor Biomarker Testing Product and Services

10.4.4 Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and

Market Share (2021-2026)

10.4.5 Thermo Fisher Scientific Recent Developments/Updates

10.4.6 Thermo Fisher Scientific Competitive Strengths & Weaknesses

10.5 QIAGEN

10.5.1 QIAGEN Details

10.5.2 QIAGEN Major Business

10.5.3 QIAGEN Tumor Biomarker Testing Product and Services

10.5.4 QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

10.5.5 QIAGEN Recent Developments/Updates

10.5.6 QIAGEN Competitive Strengths & Weaknesses

10.6 Illumina

10.6.1 Illumina Details

10.6.2 Illumina Major Business

10.6.3 Illumina Tumor Biomarker Testing Product and Services

10.6.4 Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

10.6.5 Illumina Recent Developments/Updates

10.6.6 Illumina Competitive Strengths & Weaknesses

10.7 DiaSorin

10.7.1 DiaSorin Details

10.7.2 DiaSorin Major Business

10.7.3 DiaSorin Tumor Biomarker Testing Product and Services

10.7.4 DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

10.7.5 DiaSorin Recent Developments/Updates

10.7.6 DiaSorin Competitive Strengths & Weaknesses

10.8 Fujirebio

10.8.1 Fujirebio Details

10.8.2 Fujirebio Major Business

10.8.3 Fujirebio Tumor Biomarker Testing Product and Services

10.8.4 Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

10.8.5 Fujirebio Recent Developments/Updates

10.8.6 Fujirebio Competitive Strengths & Weaknesses

10.9 Siemens Healthineers

10.9.1 Siemens Healthineers Details

10.9.2 Siemens Healthineers Major Business

10.9.3 Siemens Healthineers Tumor Biomarker Testing Product and Services

10.9.4 Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.9.5 Siemens Healthineers Recent Developments/Updates

10.9.6 Siemens Healthineers Competitive Strengths & Weaknesses

10.10 Quest Diagnostics

10.10.1 Quest Diagnostics Details

10.10.2 Quest Diagnostics Major Business

10.10.3 Quest Diagnostics Tumor Biomarker Testing Product and Services

10.10.4 Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.10.5 Quest Diagnostics Recent Developments/Updates

10.10.6 Quest Diagnostics Competitive Strengths & Weaknesses

10.11 Labcorp

10.11.1 Labcorp Details

10.11.2 Labcorp Major Business

10.11.3 Labcorp Tumor Biomarker Testing Product and Services

10.11.4 Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.11.5 Labcorp Recent Developments/Updates

10.11.6 Labcorp Competitive Strengths & Weaknesses

10.12 NeoGenomics

10.12.1 NeoGenomics Details

10.12.2 NeoGenomics Major Business

10.12.3 NeoGenomics Tumor Biomarker Testing Product and Services

10.12.4 NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.12.5 NeoGenomics Recent Developments/Updates

10.12.6 NeoGenomics Competitive Strengths & Weaknesses

10.13 Exact Sciences

10.13.1 Exact Sciences Details

10.13.2 Exact Sciences Major Business

10.13.3 Exact Sciences Tumor Biomarker Testing Product and Services

10.13.4 Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.13.5 Exact Sciences Recent Developments/Updates

10.13.6 Exact Sciences Competitive Strengths & Weaknesses

10.14 Myriad Genetics

10.14.1 Myriad Genetics Details

10.14.2 Myriad Genetics Major Business

- 10.14.3 Myriad Genetics Tumor Biomarker Testing Product and Services
- 10.14.4 Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 10.14.5 Myriad Genetics Recent Developments/Updates
- 10.14.6 Myriad Genetics Competitive Strengths & Weaknesses
- 10.15 Guardant Health
 - 10.15.1 Guardant Health Details
 - 10.15.2 Guardant Health Major Business
 - 10.15.3 Guardant Health Tumor Biomarker Testing Product and Services
 - 10.15.4 Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.15.5 Guardant Health Recent Developments/Updates
 - 10.15.6 Guardant Health Competitive Strengths & Weaknesses
- 10.16 Caris Life Sciences
 - 10.16.1 Caris Life Sciences Details
 - 10.16.2 Caris Life Sciences Major Business
 - 10.16.3 Caris Life Sciences Tumor Biomarker Testing Product and Services
 - 10.16.4 Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.16.5 Caris Life Sciences Recent Developments/Updates
 - 10.16.6 Caris Life Sciences Competitive Strengths & Weaknesses
- 10.17 Tempus AI
 - 10.17.1 Tempus AI Details
 - 10.17.2 Tempus AI Major Business
 - 10.17.3 Tempus AI Tumor Biomarker Testing Product and Services
 - 10.17.4 Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.17.5 Tempus AI Recent Developments/Updates
 - 10.17.6 Tempus AI Competitive Strengths & Weaknesses
- 10.18 Natera
 - 10.18.1 Natera Details
 - 10.18.2 Natera Major Business
 - 10.18.3 Natera Tumor Biomarker Testing Product and Services
 - 10.18.4 Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.18.5 Natera Recent Developments/Updates
 - 10.18.6 Natera Competitive Strengths & Weaknesses
- 10.19 Personalis
 - 10.19.1 Personalis Details

- 10.19.2 Personalis Major Business
- 10.19.3 Personalis Tumor Biomarker Testing Product and Services
- 10.19.4 Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 10.19.5 Personalis Recent Developments/Updates
- 10.19.6 Personalis Competitive Strengths & Weaknesses
- 10.20 Invivoscribe
 - 10.20.1 Invivoscribe Details
 - 10.20.2 Invivoscribe Major Business
 - 10.20.3 Invivoscribe Tumor Biomarker Testing Product and Services
 - 10.20.4 Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.20.5 Invivoscribe Recent Developments/Updates
 - 10.20.6 Invivoscribe Competitive Strengths & Weaknesses
- 10.21 Biocartis
 - 10.21.1 Biocartis Details
 - 10.21.2 Biocartis Major Business
 - 10.21.3 Biocartis Tumor Biomarker Testing Product and Services
 - 10.21.4 Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.21.5 Biocartis Recent Developments/Updates
 - 10.21.6 Biocartis Competitive Strengths & Weaknesses
- 10.22 Sysmex
 - 10.22.1 Sysmex Details
 - 10.22.2 Sysmex Major Business
 - 10.22.3 Sysmex Tumor Biomarker Testing Product and Services
 - 10.22.4 Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.22.5 Sysmex Recent Developments/Updates
 - 10.22.6 Sysmex Competitive Strengths & Weaknesses
- 10.23 Leica Biosystems
 - 10.23.1 Leica Biosystems Details
 - 10.23.2 Leica Biosystems Major Business
 - 10.23.3 Leica Biosystems Tumor Biomarker Testing Product and Services
 - 10.23.4 Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.23.5 Leica Biosystems Recent Developments/Updates
 - 10.23.6 Leica Biosystems Competitive Strengths & Weaknesses
- 10.24 Cepheid

- 10.24.1 Cepheid Details
- 10.24.2 Cepheid Major Business
- 10.24.3 Cepheid Tumor Biomarker Testing Product and Services
- 10.24.4 Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 10.24.5 Cepheid Recent Developments/Updates
- 10.24.6 Cepheid Competitive Strengths & Weaknesses
- 10.25 Menarini Silicon Biosystems
 - 10.25.1 Menarini Silicon Biosystems Details
 - 10.25.2 Menarini Silicon Biosystems Major Business
 - 10.25.3 Menarini Silicon Biosystems Tumor Biomarker Testing Product and Services
 - 10.25.4 Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.25.5 Menarini Silicon Biosystems Recent Developments/Updates
 - 10.25.6 Menarini Silicon Biosystems Competitive Strengths & Weaknesses
- 10.26 Veracyte
 - 10.26.1 Veracyte Details
 - 10.26.2 Veracyte Major Business
 - 10.26.3 Veracyte Tumor Biomarker Testing Product and Services
 - 10.26.4 Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.26.5 Veracyte Recent Developments/Updates
 - 10.26.6 Veracyte Competitive Strengths & Weaknesses
- 10.27 Castle Biosciences
 - 10.27.1 Castle Biosciences Details
 - 10.27.2 Castle Biosciences Major Business
 - 10.27.3 Castle Biosciences Tumor Biomarker Testing Product and Services
 - 10.27.4 Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.27.5 Castle Biosciences Recent Developments/Updates
 - 10.27.6 Castle Biosciences Competitive Strengths & Weaknesses
- 10.28 OncoDNA
 - 10.28.1 OncoDNA Details
 - 10.28.2 OncoDNA Major Business
 - 10.28.3 OncoDNA Tumor Biomarker Testing Product and Services
 - 10.28.4 OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.28.5 OncoDNA Recent Developments/Updates
 - 10.28.6 OncoDNA Competitive Strengths & Weaknesses

10.29 ACT Genomics

10.29.1 ACT Genomics Details

10.29.2 ACT Genomics Major Business

10.29.3 ACT Genomics Tumor Biomarker Testing Product and Services

10.29.4 ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.29.5 ACT Genomics Recent Developments/Updates

10.29.6 ACT Genomics Competitive Strengths & Weaknesses

10.30 GC Genome

10.30.1 GC Genome Details

10.30.2 GC Genome Major Business

10.30.3 GC Genome Tumor Biomarker Testing Product and Services

10.30.4 GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.30.5 GC Genome Recent Developments/Updates

10.30.6 GC Genome Competitive Strengths & Weaknesses

10.31 Burning Rock

10.31.1 Burning Rock Details

10.31.2 Burning Rock Major Business

10.31.3 Burning Rock Tumor Biomarker Testing Product and Services

10.31.4 Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.31.5 Burning Rock Recent Developments/Updates

10.31.6 Burning Rock Competitive Strengths & Weaknesses

10.32 Amoy Diagnostics

10.32.1 Amoy Diagnostics Details

10.32.2 Amoy Diagnostics Major Business

10.32.3 Amoy Diagnostics Tumor Biomarker Testing Product and Services

10.32.4 Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.32.5 Amoy Diagnostics Recent Developments/Updates

10.32.6 Amoy Diagnostics Competitive Strengths & Weaknesses

10.33 Genetron Health

10.33.1 Genetron Health Details

10.33.2 Genetron Health Major Business

10.33.3 Genetron Health Tumor Biomarker Testing Product and Services

10.33.4 Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

10.33.5 Genetron Health Recent Developments/Updates

- 10.33.6 Genetron Health Competitive Strengths & Weaknesses
- 10.34 3DMed Diagnostics
 - 10.34.1 3DMed Diagnostics Details
 - 10.34.2 3DMed Diagnostics Major Business
 - 10.34.3 3DMed Diagnostics Tumor Biomarker Testing Product and Services
 - 10.34.4 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.34.5 3DMed Diagnostics Recent Developments/Updates
 - 10.34.6 3DMed Diagnostics Competitive Strengths & Weaknesses
- 10.35 Singlera Genomics
 - 10.35.1 Singlera Genomics Details
 - 10.35.2 Singlera Genomics Major Business
 - 10.35.3 Singlera Genomics Tumor Biomarker Testing Product and Services
 - 10.35.4 Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.35.5 Singlera Genomics Recent Developments/Updates
 - 10.35.6 Singlera Genomics Competitive Strengths & Weaknesses
- 10.36 BGI Genomics
 - 10.36.1 BGI Genomics Details
 - 10.36.2 BGI Genomics Major Business
 - 10.36.3 BGI Genomics Tumor Biomarker Testing Product and Services
 - 10.36.4 BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.36.5 BGI Genomics Recent Developments/Updates
 - 10.36.6 BGI Genomics Competitive Strengths & Weaknesses
- 10.37 Geneseeq
 - 10.37.1 Geneseeq Details
 - 10.37.2 Geneseeq Major Business
 - 10.37.3 Geneseeq Tumor Biomarker Testing Product and Services
 - 10.37.4 Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 10.37.5 Geneseeq Recent Developments/Updates
 - 10.37.6 Geneseeq Competitive Strengths & Weaknesses
- 10.38 Genecast
 - 10.38.1 Genecast Details
 - 10.38.2 Genecast Major Business
 - 10.38.3 Genecast Tumor Biomarker Testing Product and Services
 - 10.38.4 Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

- 10.38.5 Genecast Recent Developments/Updates
- 10.38.6 Genecast Competitive Strengths & Weaknesses

11 INDUSTRY CHAIN ANALYSIS

- 11.1 Tumor Biomarker Testing Industry Chain
- 11.2 Tumor Biomarker Testing Upstream Analysis
- 11.3 Tumor Biomarker Testing Midstream Analysis
- 11.4 Tumor Biomarker Testing Downstream Analysis

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

- 13.1 Methodology
- 13.2 Research Process and Data Source
- 13.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. World Tumor Biomarker Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
- Table 2. World Tumor Biomarker Testing Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
- Table 3. World Tumor Biomarker Testing Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
- Table 4. World Tumor Biomarker Testing Revenue Market Share by Region (2021-2026), (by Headquarter Location)
- Table 5. World Tumor Biomarker Testing Revenue Market Share by Region (2027-2032), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Tumor Biomarker Testing Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
- Table 8. World Tumor Biomarker Testing Consumption Value by Region (2021-2026) & (USD Million)
- Table 9. World Tumor Biomarker Testing Consumption Value Forecast by Region (2027-2032) & (USD Million)
- Table 10. World Tumor Biomarker Testing Revenue by Player (2021-2026) & (USD Million)
- Table 11. Revenue Market Share of Key Tumor Biomarker Testing Players in 2025
- Table 12. World Tumor Biomarker Testing Industry Rank of Major Player, Based on Revenue in 2025
- Table 13. Global Tumor Biomarker Testing Company Evaluation Quadrant
- Table 14. Head Office of Key Tumor Biomarker Testing Players
- Table 15. Tumor Biomarker Testing Market: Company Product Type Footprint
- Table 16. Tumor Biomarker Testing Market: Company Product Application Footprint
- Table 17. Tumor Biomarker Testing Mergers & Acquisitions Activity
- Table 18. United States VS China Tumor Biomarker Testing Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
- Table 19. United States VS China Tumor Biomarker Testing Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
- Table 20. United States Based Tumor Biomarker Testing Companies, Headquarters (States, Country)
- Table 21. United States Based Companies Tumor Biomarker Testing Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)

Table 23. China Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)

Table 24. China Based Companies Tumor Biomarker Testing Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)

Table 26. Rest of World Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies Tumor Biomarker Testing Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)

Table 29. World Tumor Biomarker Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World Tumor Biomarker Testing Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World Tumor Biomarker Testing Market Size by Type (2027-2032) & (USD Million)

Table 32. World Tumor Biomarker Testing Market Size by Sample Source, (USD Million), 2021 & 2025 & 2032

Table 33. World Tumor Biomarker Testing Market Size Value by Sample Source (2021-2026) & (USD Million)

Table 34. World Tumor Biomarker Testing Market Size by Sample Source (2027-2032) & (USD Million)

Table 35. World Tumor Biomarker Testing Market Size by Delivery Model, (USD Million), 2021 & 2025 & 2032

Table 36. World Tumor Biomarker Testing Market Size Value by Delivery Model (2021-2026) & (USD Million)

Table 37. World Tumor Biomarker Testing Market Size by Delivery Model (2027-2032) & (USD Million)

Table 38. World Tumor Biomarker Testing Market Size by Detection Technology, (USD Million), 2021 & 2025 & 2032

Table 39. World Tumor Biomarker Testing Market Size Value by Detection Technology (2021-2026) & (USD Million)

Table 40. World Tumor Biomarker Testing Market Size by Detection Technology (2027-2032) & (USD Million)

Table 41. World Tumor Biomarker Testing Market Size by Application, (USD Million),

2021 & 2025 & 2032

Table 42. World Tumor Biomarker Testing Market Size by Application (2021-2026) & (USD Million)

Table 43. World Tumor Biomarker Testing Market Size by Application (2027-2032) & (USD Million)

Table 44. Abbott Laboratories Basic Information, Manufacturing Base and Competitors

Table 45. Abbott Laboratories Major Business

Table 46. Abbott Laboratories Tumor Biomarker Testing Product and Services

Table 47. Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 48. Abbott Laboratories Recent Developments/Updates

Table 49. Abbott Laboratories Competitive Strengths & Weaknesses

Table 50. Agilent Technologies Basic Information, Manufacturing Base and Competitors

Table 51. Agilent Technologies Major Business

Table 52. Agilent Technologies Tumor Biomarker Testing Product and Services

Table 53. Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 54. Agilent Technologies Recent Developments/Updates

Table 55. Agilent Technologies Competitive Strengths & Weaknesses

Table 56. Roche Basic Information, Manufacturing Base and Competitors

Table 57. Roche Major Business

Table 58. Roche Tumor Biomarker Testing Product and Services

Table 59. Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 60. Roche Recent Developments/Updates

Table 61. Roche Competitive Strengths & Weaknesses

Table 62. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors

Table 63. Thermo Fisher Scientific Major Business

Table 64. Thermo Fisher Scientific Tumor Biomarker Testing Product and Services

Table 65. Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 66. Thermo Fisher Scientific Recent Developments/Updates

Table 67. Thermo Fisher Scientific Competitive Strengths & Weaknesses

Table 68. QIAGEN Basic Information, Manufacturing Base and Competitors

Table 69. QIAGEN Major Business

Table 70. QIAGEN Tumor Biomarker Testing Product and Services

Table 71. QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

- Table 72. QIAGEN Recent Developments/Updates
- Table 73. QIAGEN Competitive Strengths & Weaknesses
- Table 74. Illumina Basic Information, Manufacturing Base and Competitors
- Table 75. Illumina Major Business
- Table 76. Illumina Tumor Biomarker Testing Product and Services
- Table 77. Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 78. Illumina Recent Developments/Updates
- Table 79. Illumina Competitive Strengths & Weaknesses
- Table 80. DiaSorin Basic Information, Manufacturing Base and Competitors
- Table 81. DiaSorin Major Business
- Table 82. DiaSorin Tumor Biomarker Testing Product and Services
- Table 83. DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 84. DiaSorin Recent Developments/Updates
- Table 85. DiaSorin Competitive Strengths & Weaknesses
- Table 86. Fujirebio Basic Information, Manufacturing Base and Competitors
- Table 87. Fujirebio Major Business
- Table 88. Fujirebio Tumor Biomarker Testing Product and Services
- Table 89. Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 90. Fujirebio Recent Developments/Updates
- Table 91. Fujirebio Competitive Strengths & Weaknesses
- Table 92. Siemens Healthineers Basic Information, Manufacturing Base and Competitors
- Table 93. Siemens Healthineers Major Business
- Table 94. Siemens Healthineers Tumor Biomarker Testing Product and Services
- Table 95. Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 96. Siemens Healthineers Recent Developments/Updates
- Table 97. Siemens Healthineers Competitive Strengths & Weaknesses
- Table 98. Quest Diagnostics Basic Information, Manufacturing Base and Competitors
- Table 99. Quest Diagnostics Major Business
- Table 100. Quest Diagnostics Tumor Biomarker Testing Product and Services
- Table 101. Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 102. Quest Diagnostics Recent Developments/Updates
- Table 103. Quest Diagnostics Competitive Strengths & Weaknesses
- Table 104. Labcorp Basic Information, Manufacturing Base and Competitors

- Table 105. Labcorp Major Business
- Table 106. Labcorp Tumor Biomarker Testing Product and Services
- Table 107. Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 108. Labcorp Recent Developments/Updates
- Table 109. Labcorp Competitive Strengths & Weaknesses
- Table 110. NeoGenomics Basic Information, Manufacturing Base and Competitors
- Table 111. NeoGenomics Major Business
- Table 112. NeoGenomics Tumor Biomarker Testing Product and Services
- Table 113. NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 114. NeoGenomics Recent Developments/Updates
- Table 115. NeoGenomics Competitive Strengths & Weaknesses
- Table 116. Exact Sciences Basic Information, Manufacturing Base and Competitors
- Table 117. Exact Sciences Major Business
- Table 118. Exact Sciences Tumor Biomarker Testing Product and Services
- Table 119. Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 120. Exact Sciences Recent Developments/Updates
- Table 121. Exact Sciences Competitive Strengths & Weaknesses
- Table 122. Myriad Genetics Basic Information, Manufacturing Base and Competitors
- Table 123. Myriad Genetics Major Business
- Table 124. Myriad Genetics Tumor Biomarker Testing Product and Services
- Table 125. Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 126. Myriad Genetics Recent Developments/Updates
- Table 127. Myriad Genetics Competitive Strengths & Weaknesses
- Table 128. Guardant Health Basic Information, Manufacturing Base and Competitors
- Table 129. Guardant Health Major Business
- Table 130. Guardant Health Tumor Biomarker Testing Product and Services
- Table 131. Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 132. Guardant Health Recent Developments/Updates
- Table 133. Guardant Health Competitive Strengths & Weaknesses
- Table 134. Caris Life Sciences Basic Information, Manufacturing Base and Competitors
- Table 135. Caris Life Sciences Major Business
- Table 136. Caris Life Sciences Tumor Biomarker Testing Product and Services
- Table 137. Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

- Table 138. Caris Life Sciences Recent Developments/Updates
- Table 139. Caris Life Sciences Competitive Strengths & Weaknesses
- Table 140. Tempus AI Basic Information, Manufacturing Base and Competitors
- Table 141. Tempus AI Major Business
- Table 142. Tempus AI Tumor Biomarker Testing Product and Services
- Table 143. Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 144. Tempus AI Recent Developments/Updates
- Table 145. Tempus AI Competitive Strengths & Weaknesses
- Table 146. Natera Basic Information, Manufacturing Base and Competitors
- Table 147. Natera Major Business
- Table 148. Natera Tumor Biomarker Testing Product and Services
- Table 149. Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 150. Natera Recent Developments/Updates
- Table 151. Natera Competitive Strengths & Weaknesses
- Table 152. Personalis Basic Information, Manufacturing Base and Competitors
- Table 153. Personalis Major Business
- Table 154. Personalis Tumor Biomarker Testing Product and Services
- Table 155. Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 156. Personalis Recent Developments/Updates
- Table 157. Personalis Competitive Strengths & Weaknesses
- Table 158. Invivoscribe Basic Information, Manufacturing Base and Competitors
- Table 159. Invivoscribe Major Business
- Table 160. Invivoscribe Tumor Biomarker Testing Product and Services
- Table 161. Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 162. Invivoscribe Recent Developments/Updates
- Table 163. Invivoscribe Competitive Strengths & Weaknesses
- Table 164. Biocartis Basic Information, Manufacturing Base and Competitors
- Table 165. Biocartis Major Business
- Table 166. Biocartis Tumor Biomarker Testing Product and Services
- Table 167. Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 168. Biocartis Recent Developments/Updates
- Table 169. Biocartis Competitive Strengths & Weaknesses
- Table 170. Sysmex Basic Information, Manufacturing Base and Competitors
- Table 171. Sysmex Major Business

- Table 172. Sysmex Tumor Biomarker Testing Product and Services
- Table 173. Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 174. Sysmex Recent Developments/Updates
- Table 175. Sysmex Competitive Strengths & Weaknesses
- Table 176. Leica Biosystems Basic Information, Manufacturing Base and Competitors
- Table 177. Leica Biosystems Major Business
- Table 178. Leica Biosystems Tumor Biomarker Testing Product and Services
- Table 179. Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 180. Leica Biosystems Recent Developments/Updates
- Table 181. Leica Biosystems Competitive Strengths & Weaknesses
- Table 182. Cepheid Basic Information, Manufacturing Base and Competitors
- Table 183. Cepheid Major Business
- Table 184. Cepheid Tumor Biomarker Testing Product and Services
- Table 185. Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 186. Cepheid Recent Developments/Updates
- Table 187. Cepheid Competitive Strengths & Weaknesses
- Table 188. Menarini Silicon Biosystems Basic Information, Manufacturing Base and Competitors
- Table 189. Menarini Silicon Biosystems Major Business
- Table 190. Menarini Silicon Biosystems Tumor Biomarker Testing Product and Services
- Table 191. Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 192. Menarini Silicon Biosystems Recent Developments/Updates
- Table 193. Menarini Silicon Biosystems Competitive Strengths & Weaknesses
- Table 194. Veracyte Basic Information, Manufacturing Base and Competitors
- Table 195. Veracyte Major Business
- Table 196. Veracyte Tumor Biomarker Testing Product and Services
- Table 197. Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 198. Veracyte Recent Developments/Updates
- Table 199. Veracyte Competitive Strengths & Weaknesses
- Table 200. Castle Biosciences Basic Information, Manufacturing Base and Competitors
- Table 201. Castle Biosciences Major Business
- Table 202. Castle Biosciences Tumor Biomarker Testing Product and Services
- Table 203. Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

- Table 204. Castle Biosciences Recent Developments/Updates
- Table 205. Castle Biosciences Competitive Strengths & Weaknesses
- Table 206. OncoDNA Basic Information, Manufacturing Base and Competitors
- Table 207. OncoDNA Major Business
- Table 208. OncoDNA Tumor Biomarker Testing Product and Services
- Table 209. OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 210. OncoDNA Recent Developments/Updates
- Table 211. OncoDNA Competitive Strengths & Weaknesses
- Table 212. ACT Genomics Basic Information, Manufacturing Base and Competitors
- Table 213. ACT Genomics Major Business
- Table 214. ACT Genomics Tumor Biomarker Testing Product and Services
- Table 215. ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 216. ACT Genomics Recent Developments/Updates
- Table 217. ACT Genomics Competitive Strengths & Weaknesses
- Table 218. GC Genome Basic Information, Manufacturing Base and Competitors
- Table 219. GC Genome Major Business
- Table 220. GC Genome Tumor Biomarker Testing Product and Services
- Table 221. GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 222. GC Genome Recent Developments/Updates
- Table 223. GC Genome Competitive Strengths & Weaknesses
- Table 224. Burning Rock Basic Information, Manufacturing Base and Competitors
- Table 225. Burning Rock Major Business
- Table 226. Burning Rock Tumor Biomarker Testing Product and Services
- Table 227. Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 228. Burning Rock Recent Developments/Updates
- Table 229. Burning Rock Competitive Strengths & Weaknesses
- Table 230. Amoy Diagnostics Basic Information, Manufacturing Base and Competitors
- Table 231. Amoy Diagnostics Major Business
- Table 232. Amoy Diagnostics Tumor Biomarker Testing Product and Services
- Table 233. Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 234. Amoy Diagnostics Recent Developments/Updates
- Table 235. Amoy Diagnostics Competitive Strengths & Weaknesses
- Table 236. Genetron Health Basic Information, Manufacturing Base and Competitors
- Table 237. Genetron Health Major Business

- Table 238. Genetron Health Tumor Biomarker Testing Product and Services
- Table 239. Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 240. Genetron Health Recent Developments/Updates
- Table 241. Genetron Health Competitive Strengths & Weaknesses
- Table 242. 3DMed Diagnostics Basic Information, Manufacturing Base and Competitors
- Table 243. 3DMed Diagnostics Major Business
- Table 244. 3DMed Diagnostics Tumor Biomarker Testing Product and Services
- Table 245. 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 246. 3DMed Diagnostics Recent Developments/Updates
- Table 247. 3DMed Diagnostics Competitive Strengths & Weaknesses
- Table 248. Singlera Genomics Basic Information, Manufacturing Base and Competitors
- Table 249. Singlera Genomics Major Business
- Table 250. Singlera Genomics Tumor Biomarker Testing Product and Services
- Table 251. Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 252. Singlera Genomics Recent Developments/Updates
- Table 253. Singlera Genomics Competitive Strengths & Weaknesses
- Table 254. BGI Genomics Basic Information, Manufacturing Base and Competitors
- Table 255. BGI Genomics Major Business
- Table 256. BGI Genomics Tumor Biomarker Testing Product and Services
- Table 257. BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 258. BGI Genomics Recent Developments/Updates
- Table 259. BGI Genomics Competitive Strengths & Weaknesses
- Table 260. Geneseeq Basic Information, Manufacturing Base and Competitors
- Table 261. Geneseeq Major Business
- Table 262. Geneseeq Tumor Biomarker Testing Product and Services
- Table 263. Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 264. Geneseeq Recent Developments/Updates
- Table 265. Geneseeq Competitive Strengths & Weaknesses
- Table 266. Genecast Basic Information, Manufacturing Base and Competitors
- Table 267. Genecast Major Business
- Table 268. Genecast Tumor Biomarker Testing Product and Services
- Table 269. Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 270. Genecast Recent Developments/Updates

Table 271. Genecast Competitive Strengths & Weaknesses

Table 272. Global Key Players of Tumor Biomarker Testing Upstream (Raw Materials)

Table 273. Global Tumor Biomarker Testing Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Tumor Biomarker Testing Picture
- Figure 2. World Tumor Biomarker Testing Total Revenue: 2021 & 2025 & 2032, (USD Million)
- Figure 3. World Tumor Biomarker Testing Total Revenue (2021-2032) & (USD Million)
- Figure 4. World Tumor Biomarker Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
- Figure 5. World Tumor Biomarker Testing Revenue Market Share by Region (2021-2032), (by Headquarter Location)
- Figure 6. United States Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
- Figure 7. China Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
- Figure 8. Europe Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
- Figure 9. Japan Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
- Figure 10. South Korea Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
- Figure 11. ASEAN Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
- Figure 12. India Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
- Figure 13. Tumor Biomarker Testing Market Drivers
- Figure 14. Factors Affecting Demand
- Figure 15. World Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
- Figure 16. World Tumor Biomarker Testing Consumption Value Market Share by Region (2021-2032)
- Figure 17. United States Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
- Figure 18. China Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
- Figure 19. Europe Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
- Figure 20. Japan Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Million)

Figure 21. South Korea Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 23. India Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of Tumor Biomarker Testing by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for Tumor Biomarker Testing Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for Tumor Biomarker Testing Markets in 2025

Figure 27. United States VS China: Tumor Biomarker Testing Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: Tumor Biomarker Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World Tumor Biomarker Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World Tumor Biomarker Testing Market Size Market Share by Type in 2025

Figure 31. DNA Biomarker Testing

Figure 32. RNA Biomarker Testing

Figure 33. Protein Biomarker Testing

Figure 34. Cell-based Biomarker Testing

Figure 35. Multi-analyte Biomarker Testing

Figure 36. World Tumor Biomarker Testing Market Size Market Share by Type (2021-2032)

Figure 37. World Tumor Biomarker Testing Market Size by Sample Source, (USD Million), 2021 & 2025 & 2032

Figure 38. World Tumor Biomarker Testing Market Size Market Share by Sample Source in 2025

Figure 39. Tissue-based Testing

Figure 40. Blood-based Testing

Figure 41. Bone Marrow-based Testing

Figure 42. Other Body Fluid-based Testing

Figure 43. World Tumor Biomarker Testing Market Size Market Share by Sample Source (2021-2032)

Figure 44. World Tumor Biomarker Testing Market Size by Delivery Model, (USD Million), 2021 & 2025 & 2032

Figure 45. World Tumor Biomarker Testing Market Size Market Share by Delivery Model in 2025

Figure 46. Central Laboratory Testing

Figure 47. Hospital In-house Testing

Figure 48. World Tumor Biomarker Testing Market Size Market Share by Delivery Model (2021-2032)

Figure 49. World Tumor Biomarker Testing Market Size by Detection Technology, (USD Million), 2021 & 2025 & 2032

Figure 50. World Tumor Biomarker Testing Market Size Market Share by Detection Technology in 2025

Figure 51. Sequencing-based Testing

Figure 52. PCR-based Testing

Figure 53. Immunoassay-based Testing

Figure 54. Hybridization-based Testing

Figure 55. Cell Analysis-based Testing

Figure 56. World Tumor Biomarker Testing Market Size Market Share by Detection Technology (2021-2032)

Figure 57. World Tumor Biomarker Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 58. World Tumor Biomarker Testing Market Size Market Share by Application in 2025

Figure 59. Lung Cancer

Figure 60. Breast Cancer

Figure 61. Colorectal

Figure 62. Prostate Cancer

Figure 63. Blood Cancer

Figure 64. World Tumor Biomarker Testing Market Size Market Share by Application (2021-2032)

Figure 65. Tumor Biomarker Testing Industrial Chain

Figure 66. Methodology

Figure 67. Research Process and Data Source

I would like to order

Product name: Global Tumor Biomarker Testing Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G395A9EEA87DEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G395A9EEA87DEN.html>